

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 22, 2008

InfuSystem Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

0-51902
(Commission File Number)

20-3341405
(I.R.S. Employer
Identification No.)

**1551 East Lincoln Avenue, Suite 200
Madison Heights, Michigan 48071**
(Address of principal executive offices) (Zip Code)

**Registrant's telephone number, including area code:
(248) 546-7047**

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 22, 2008, at a regularly scheduled meeting of the Board of Directors of InfuSystem Holdings, Inc. (the "Company"), the Board elected James L. Freddo, M.D. and David C. Dreyer to serve as members of the Board of Directors of the Company, effective as of April 22, 2008. Mr. Dreyer was also appointed as the Chairman of the Audit Committee of the Board of Directors. Dr. Freddo and Mr. Dreyer will serve as members of the Board of Directors until the annual meeting of the stockholders on May 20, 2008, at which time they will stand for re-election.

In connection with the appointment of Dr. Freddo and Mr. Dreyer to the Board of Directors, the Board authorized the grant of a stock option to each of them exercisable for 40,000 shares of the Company's common stock, par value \$0.0001 per share, 50% of the shares subject to such stock options to vest on the date of grant and the remaining 50% of such shares to vest on the one year anniversary of the date of grant.

Item 7.01 Regulation FD Disclosure

On April 28, 2008, the Company issued a press release announcing the appointment of Dr. Freddo and Mr. Dreyer to the Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release issued by InfuSystem Holdings, Inc. on April 28, 2008

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.

By: /s/ Steve Watkins

Steve Watkins

Chief Executive Officer

(Duly Authorized Officer and Principal
Executive Officer)

Dated: April 28, 2008

Index to Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by InfuSystem Holdings, Inc. on April 28, 2008

InfuSystem Holdings Appoints Two New Board Members

Monday April 28, 7:30 am ET

NEW YORK, April 28 /PRNewswire-FirstCall/ — InfuSystem Holdings, Inc. (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced the appointment of David C. Dreyer and James L. Freddo, M.D. to the board of directors, bringing the total to eight members.

Mr. Dreyer has served as chief financial officer, chief accounting officer and treasurer of AMN Healthcare Services, Inc. (NYSE: AHS—News) since September 2004. Prior to that, he served as chief financial officer and chief accounting officer of Sicom, Inc., a manufacturer of complex pharmaceuticals with operations in the United States, Italy, Mexico, Lithuania, China and Switzerland, which was acquired by Teva Pharmaceutical Limited. Prior to joining Sicom in 1997, Mr. Dreyer served in related senior financial positions within the pharmaceutical industry for companies such as Elan Corporation plc, Athena Neurosciences and Syntex. Mr. Dreyer holds a Bachelors Degree from Golden Gate University in San Francisco and is a certified public accountant in California.

Dr. Freddo has served as chief medical officer of Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS—News) since July 2006. Prior to joining Anadys Pharmaceuticals, Dr. Freddo served as vice president, clinical site head and development site head at Pfizer Global Research and Development, La Jolla. From June 2002 until August 2005, Dr. Freddo served as executive director and site therapeutic area leader for oncology clinical development in La Jolla. While at Pfizer, Dr. Freddo led the team responsible for the registration of Sutent® (sunitinib malate), a drug approved by the U.S. Food and Drug Administration in January 2006 for the treatment of advanced kidney cancer and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Freddo held a variety of senior management positions at Wyeth-Ayerst Research from December 1996 until June 2002, including senior director, oncology, senior director, infectious diseases, and senior director, transplantation immunology. Dr. Freddo holds a B.S. degree in Medical Technology from the State University of New York at Stony Brook and an M.D. degree from the University of North Carolina, where he also completed his fellowship training.

Mr. Sean McDevitt, chairman of the board, commented, “We are pleased to welcome David and James as the newest members of our board of directors, both of whom share our vision and commitment to improving the lives of cancer patients and helping to build InfuSystem into a world-class provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients. David has the ideal combination of both financial and healthcare experience, which will make him a valuable addition to our audit committee. James brings extensive medical and clinical experience, which will be an important resource as we accelerate our outreach activities within the healthcare community.”

About InfuSystem Holdings, Inc.

InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one’s home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem’s pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.